NCT03775265 2026-03-18
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
21 trialsNCT04164082 2026-03-18
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05987241 2026-03-18
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT07061964 2026-03-18
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03258593 2026-03-17
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT07180212 2026-03-17
Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer
Tianjin Medical University Second Hospital
Phase NA Recruiting
NCT07000084 2026-03-04
GAIN-BCG
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT05796375 2026-01-30
ReplaceCysto
White River Junction Veterans Affairs Medical Center
Phase 2 Recruiting
NCT04216290 2025-11-12
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05564416 2025-10-21
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT06704191 2025-09-22
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
Phase 1/2 Recruiting
NCT05438563 2025-09-09
MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer
Mayo Clinic
Phase NA Recruiting
NCT06944314 2025-04-27
Physicians' Perception About Patient Pain in Flexible Cystoscopy With Local Anesthesia
Marmara University
Phase NA Enrolling by invitation
NCT06422312 2025-04-04
A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients.
Guangzhou Red Pine Medical Instrument Co., Ltd.
Phase NA Withdrawn
NCT02901548 2022-07-29
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT05362539 2022-05-05
Novel Urine-Based DNA Methylation Biomarkers for Urothelial Bladder Carcinoma Detection in Patients With Hematuria
Mansoura University
Phase NA Completed
NCT02700464 2021-05-04
The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma
Nucleix Ltd.
Phase NA Completed
NCT03831321 2019-02-05
The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy
Istanbul Medeniyet University
Phase 4 Unknown
NCT02145390 2018-08-28
Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy
University of Miami
Phase NA Terminated
NCT00556621 2015-07-30
GEMCIRAV
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 1/2 Completed
NCT00052637 2013-10-23
Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer
Photocure
Phase 3 Completed